Ocera Therapeutics 10-Q 13 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 31, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'Ocera Therapeutics, Inc.	'
Entity Central Index Key	'0001274644	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	19,741,758

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$8,327	$15,533
Short-term investments, available-for-sale	46,911	30,167
Accounts receivable	32	93
Prepaid expenses and other current assets	1,123	470
Assets of discontinued operations	0	3,029
Current assets	56,393	49,292
Property and equipment, net	69	59
Long-term investments	392	1,513
Other non-current assets	26	26
Intangible assets, net	212	335
Goodwill	595	595
Total assets	57,687	51,820
Current liabilities:	'	'
Accounts payable	1,056	1,282
Accrued liabilities	1,914	1,902
Liabilities of discontinued operations	0	3,503
Total current liabilities	2,970	6,687
Other liabilities	2	1
Total liabilities	2,972	6,688
Commitments and contingencies (Note 9)	'	'
Stockholders' equity:	'	'
Preferred stock - $0.00001 par value, 5,000,000 shares authorized and no shares issued or outstanding at September 30, 2014 and December 31, 2013.	0	0
Common stock - $0.00001 par value, 100,000,000 shares authorized, 19,741,758 and 15,300,214 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively.	0	0
Additional paid-in capital	154,098	126,615
Accumulated other comprehensive income (loss)	-6	3
Accumulated deficit	-99,377	-81,486
Total stockholders' equity	54,715	45,132
Total liabilities and stockholders' equity	$57,687	$51,820

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	19,741,758	15,300,214
Common stock, shares outstanding	19,741,758	15,300,214

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue:	'	'	'	'
Licensing revenue	$200	$0	$200	$0
Royalty revenue	33	33	111	33
Total revenue	233	33	311	33
Operating expenses:	'	'	'	'
Research and development	4,189	1,351	11,481	1,785
General and administrative	2,682	2,990	7,836	5,213
Amortization of intangibles	41	172	123	172
Impairment of intangibles	0	1,576	0	1,576
Total operating expenses	6,912	6,089	19,440	8,746
Other income (expense):	'	'	'	'
Interest and other income	18	1	43	1
Interest and other expense	0	-13	0	-186
Change in fair value of warrant liability	0	3	0	15
Total other income (expense), net	18	-9	43	-170
Net loss from continuing operations	-6,661	-6,065	-19,086	-8,883
Net income (loss) from discontinued operations (including gain on disposal of $- and $1,149 for the three and nine months ended September 30, 2014)	58	-1,337	1,195	-1,337
Net loss	-6,603	-7,402	-17,891	-10,220
Net loss per share:	'	'	'	'
Net loss per share from continuing operations, basic and diluted	($0.34)	($0.63)	($1.14)	($2.41)
Net income (loss) per share from discontinued operations, basic and diluted	$0	($0.14)	$0.07	($0.36)
Net loss per share, basic and diluted	($0.34)	($0.77)	($1.07)	($2.77)
Weighted average number of shares used to compute net loss per share of common stock, basic and diluted	19,330,888	9,669,320	16,778,047	3,683,156
Other comprehensive loss:	'	'	'	'
Net loss	-6,603	-7,402	-17,891	-10,220
Unrealized loss on investments	-10	0	-9	0
Comprehensive loss	($6,613)	($7,402)	($17,900)	($10,220)

Consolidated_Statements_of_Ope1

Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Gain on disposal of assets	$0	'	$1,149	'
Tranzyme Pharma Inc. [Member]	'	'	'	'
Gain on disposal of assets	$0	$0	$1,149	$0

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Operating activities	'	'
Net loss	($17,891)	($10,220)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Net income (loss) from discontinued operations	-1,195	1,337
Depreciation	28	15
Amortization of intangibles	123	172
Stock based compensation	3,701	234
Change in valuation of warrant liability	0	-15
Impairment of intangible assets	0	1,576
Accretion of premium on investment securities	409	0
Debt discount, net and noncash interest expense	0	92
Changes in operating assets and liabilities:	'	'
Accounts receivable	61	72
Prepaid expenses and other assets	-653	-316
Accounts payable	-239	-534
Accrued liabilities	-29	0
Net cash used in continuing operating activities	-15,685	-7,587
Net cash used in discontinued operating activities	-444	-479
Net cash used in operating activities	-16,129	-8,066
Investing activities	'	'
Purchases of property and equipment	-38	-6
Purchase of investments	-35,586	0
Sale and maturities of investments	19,545	0
Cash received from merger transaction	0	7,464
Net cash provided by (used in) continuing investing activities	-16,079	7,458
Net cash provided by discontinued investing activities	1,165	0
Net cash provided by (used in) investing activities	-14,914	7,458
Financing activities	'	'
Proceeds from the sale of common stock, net of underwriting discounts and commissions and offering expenses	23,439	19,973
Proceeds from exercise of common stock options	398	23
Net cash provided by continuing financing activities	23,837	19,996
Net increase (decrease) in cash and cash equivalents	-7,206	19,388
Cash and cash equivalentsbbeginning of period	15,533	2,303
Cash and cash equivalentsbend of period	8,327	21,691
Supplemental schedule of noncash investing and financing activities	'	'
Cashless exercise of stock options	22	0
Unrealized loss on investments	9	0
Deferred offering costs in accrued expenses and accounts payable	55	0
Reclassification of warrant liability to additional paid-in-capital	0	1
Conversion of promissory note and interest to common stock	0	3,187
Conversion of preferred stock to common stock	0	61,743
Common stock issued in connection with merger transaction	$0	$13,524

The_Company

The Company	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
The Company	'
	The Company
	Ocera Therapeutics, Inc. (the "Company") is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate). OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status from the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute or chronic liver disease.
	On July 15, 2013, Terrapin Acquisition, Inc., a Delaware corporation (“Merger Sub”) and wholly owned subsidiary of Tranzyme, Inc., a Delaware corporation (“Tranzyme”), completed its merger (the “Merger”) with and into Ocera Therapeutics, Inc., a private Delaware corporation (“Private Ocera”).  Private Ocera is considered the acquiring company in the Merger for accounting purposes.  In connection with the Merger, the combined company changed its name to Ocera Therapeutics, Inc. and the name of Private Ocera was changed to Ocera Subsidiary, Inc.
	On July 10, 2014 the Company completed an underwritten public offering of its common stock in which 4,200,000 shares of common stock were sold by the Company. The aggregate gross proceeds from the offering were $25.2 million. After deducting underwriters' discounts and commissions and offering expenses, the aggregate net proceeds received by the Company totaled approximately $23.4 million. The Company expects to use the net proceeds from the offering to continue its clinical development of OCR-002 and for working capital and other general corporate purposes.
	The Company has incurred net losses since its inception and, as of September 30, 2014, had an accumulated deficit of $99.4 million and had cash, cash equivalents and investments of $55.6 million.
	The Company has evaluated subsequent events and transactions for potential recognition or disclosure in the financial statements through the day the financial statements are issued.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Summary of Significant Accounting Policies
	Basis of Presentation
	The Company has a limited operating history and the sales and income potential of the Company's business and addressable market are unproven. The Company anticipates that it will continue to incur net losses into the foreseeable future as it continues the development and commercialization of its lead drug candidate OCR-002 and expands its corporate infrastructure. Based on the Company's operating plan, the Company believes its current working capital is sufficient to fund its operations through at least the next twelve months.
	The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with United States of America generally accepted accounting principles ("U.S. GAAP") for interim financial statements and pursuant to the rules and regulations of the Securities and Exchange Commission. The financial statements and related notes do not include all information and footnotes required by U.S. GAAP for annual reports. This quarterly report should be read in conjunction with the consolidated financial statements included in the Company’s annual report on Form 10-K for the year ended December 31, 2013. Certain prior year amounts have been reclassified to conform with current year presentation.
	Unaudited Interim Financial Information
	The accompanying interim consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. The year-end balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period.
	Use of Estimates
	The preparation of financial statements in conformity with the U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
	Discontinued Operations
	On September 11, 2013, the Board of Directors approved a restructuring plan related to the operations of Tranzyme Pharma Inc. and its Sherbrooke, Quebec facility ("Tranzyme Pharma"), whereby the Company closed the operations of the facility effective as of November 11, 2013. On December 13, 2013, the Company entered into a Technology Transfer and License Agreement to sell the Company’s MATCH discovery platform and license the related intellectual property rights. The Company concluded that since Tranzyme Pharma's operations and the MATCH discovery platform comprised a component with distinct operations and cash flows that would be eliminated from ongoing operations, and the Company would not have significant involvement after the disposal, these components would be accounted for as discontinued operations. The results of operations of the components to be disposed of, related restructuring costs and gain on disposal of assets have been classified as net income (loss) from discontinued operations from their date of acquisition on July 15, 2013 through September 30, 2014. The assets and liabilities of Tranzyme Pharma have been classified as assets and liabilities, respectively, of discontinued operations. Discontinued operations are retroactively applied to all prior periods presented, and the financial statements presented for 2013 are reclassified to recognize the effects of discontinued operations. Unless noted otherwise, discussion in these notes to the financial statements pertain to our continuing operations.
	Revenue Recognition
	The Company recognizes revenue from the delivery of collaborative research services, license agreements for the development and commercialization of products and from royalties. During 2013, collaboration research revenue is disclosed as discontinued operations in the Company’s Consolidated Statements of Operation and Comprehensive Loss for all periods presented. For each source of revenue, the Company applies revenue recognition criteria in the following manner:
	Multiple element arrangements such as collaboration agreements which may include an upfront license and ongoing services are analyzed to determine whether the deliverables within the agreement can be separated or whether they must be accounted for as a single unit of accounting. Deliverables under the agreement will be accounted for as separate units of accounting provided that (i) a delivered item has value to the customer on a stand-alone basis; and (ii) if the agreement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially in the control of the vendor. The allocation of consideration amongst the deliverables under the agreement is derived using a "best estimate of selling price" if vendor specific objective evidence and third-party evidence of fair value is not available. If the delivered element does not have stand-alone value, the arrangement is then accounted for as a single unit of accounting, and the Company will recognize the consideration received under the arrangement as revenue on a straight-line basis over the estimated period of performance.
	License fees from license agreements are recognized when the amounts are earned and determinable during the applicable period. The Company recognizes up-front nonrefundable license fees when due under contractual agreements and when the Company does not have a continuing obligation to provide services related to the agreement. Revenue associated with nonrefundable up-front license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting is deferred and recognized as revenue on a straight-line basis over the expected term of our continued involvement in the research and development process.
	The Company recognizes royalty payments as revenue when earned. At the end of each accounting period, estimates of royalty amounts due are made based on estimated sales information from the Company's customers.
	Recent Accounting Pronouncements
	In April 2014, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update, or ASU, No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant and Equipment (topic 360); Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. ASU 2014-08 provides additional requirements to classify a disposal of a component of an entity or a group of components of an entity in discontinued operations only if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2014, with an option for early adoption. The Company intends to adopt this guidance at the beginning of our first quarter of fiscal year 2015, and does not expect the adoption of this standard will have a material impact on the Company’s financial statements.
	On May 28, 2014, the FASB issued Accounting Standards Update, or ASU, No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard will become effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.
	In June 2014, the FASB issued Accounting Standards Update, or ASU, No. 2014-10, Development Stage Entities (Topic 915). ASU 2014-10 removes the distinction between development stage entities and other reporting entities in U.S. GAAP and eliminates the requirement to label financial statements as those of a development stage entity and eliminates the requirement to present inception to date information in the statements of income, cash flows and shareholder equity. The guidance is applied retroactively and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2014, with an option for early adoption. The Company early adopted this guidance in the second quarter of 2014, and as a result, has removed the label “A Development Stage Company” from its financial statements and accompanying notes and eliminated the inception to date information from the Consolidated Statements of Operations and Comprehensive Loss and Consolidated Statements of Cash Flows. Other than presentation, the adoption of this standard did not have a material impact on the Company’s financial statements.
	In August 2014, the FASB issued Accounting Standards Update, or ASU, No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. In doing so, companies will have reduced diversity in the timing and content of footnote disclosures than under today’s guidance. ASU 2014-15 is effective for the Company in the first quarter of 2016 with early adoption permitted. The Company does not believe the impact of adopting this standard will be material on the Company's financial statements.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Fair Value Measurements
	The following tables present information about the Company’s financial assets measured at fair value on a recurring basis as of September 30, 2014, and December 31, 2013, and indicate the fair value hierarchy of the valuation techniques utilized by the Company to determine such fair value. As a basis for categorizing inputs, the Company uses a three-tier fair value hierarchy, which prioritizes the inputs used to measure fair value from market-based assumptions to entity specific assumptions:
	Level 1: Quoted prices in active markets for identical assets or liabilities;
	Level 2: Inputs, other than level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
	Level 3: Unobservable inputs that are supported by little or no market activity, which require the Company to develop its own assumptions.
	Assets measured at fair value on a recurring basis as of September 30, 2014 are as follows (in thousands):
		Balance as of		Quoted Prices		Significant		Significant
		September 30,		in Active		Other		Unobservable
		2014		Markets for		Observable		Inputs
				Identical Assets		Inputs		(Level 3)
				(Level 1)		(Level 2)
	Assets:
	Money market funds	$	7,445	$	7,445	$	—	$	—
	Commercial paper	5,250		—		5,250		—
	Corporate debt securities	42,053		—		42,053		—
	Total assets	$	54,748	$	7,445	$	47,303	$	—
	Assets measured at fair value on a recurring basis as of December 31, 2013 are as follows (in thousands):
		Balance as of		Quoted Prices		Significant		Significant
		December 31,		in Active		Other		Unobservable
		2013		Markets for		Observable		Inputs
				Identical Assets		Inputs		(Level 3)
				(Level 1)		(Level 2)
	Assets:
	Money market funds	$	5,774	$	5,774	$	—	$	—
	Commercial paper	15,246		—		15,246		—
	Corporate debt securities	20,884		—		20,884		—
	Total assets	$	41,904	$	5,774	$	36,130	$	—

Balance_Sheet_Components

Balance Sheet Components	9 Months Ended
	Sep. 30, 2014
Balance Sheet Components [Abstract]	'
Balance Sheet Components	'
	Balance Sheet Components
	Investments
	The following table summarizes the Company's available for sale investments as of September 30, 2014 (in thousands).
			Maturity (in Years)		Amortized Cost				Unrealized Gains		Unrealized Losses			Estimated Fair Value
	Short-term investments:
	Commercial paper		1 or less		5,246				4		—			5,250
	Corporate debt securities		1 or less		41,671				—		(10		)	41,661
	Total				46,917				4		(10		)	46,911
	Long-term investments:
	Corporate debt securities		More than 1		392				—		—			392
	Total				392				—		—			392
	Total investments				$	47,309			$	4	$	(10	)	$	47,303
	The following table summarizes the Company's available for sale investments as of December 31, 2013 (in thousands).
			Maturity (in Years)		Amortized Cost				Unrealized Gains		Unrealized Losses			Estimated Fair Value
	Short-term investments:
	Commercial paper		1 or less		$	15,232			$	14	$	—		$	15,246
	Corporate debt securities		1 or less		14,930				—		(9		)	14,921
	Total				30,162				14		(9		)	30,167
	Long-term investments:
	Corporate debt securities		More than 1		1,515				—		(2		)	1,513
	Total				1,515				—		(2		)	1,513
	Total investments				$	31,677			$	14	$	(11	)	$	31,680
	At each reporting date, the Company performs an evaluation of impairment to determine if the unrealized losses are other-than-temporary. For debt securities, management determines whether it intends to sell the impaired securities, and if there is no intent or expected requirement to sell, management considers whether it is likely that the amortized cost will be recovered. The Company does not consider unrealized losses on its debt investment securities to be credit-related. These unrealized losses relate to changes in interest rates and market spreads subsequent to purchase. The Company has not made a decision to sell securities with unrealized losses and believes it is more likely than not it would not be required to sell such securities before recovery of its amortized cost. There have been no other than temporary losses recognized in earnings.
	Property and Equipment
	Property and equipment, net were as follows (in thousands):
		Useful Life		September 30,				December 31,
		(in years)		2014				2013
	Computer equipment and software	3 years		$	53			$	40
	Office furniture and equipment	5 years		68				43
				121				83
	Accumulated depreciation			(52		)		(24		)
	Property and equipment, net			$	69			$	59
	Total depreciation expense was $8,000 and $11,000 for the three months ended September 30, 2014 and 2013, respectively, $28,000 and $15,000 for the nine months ended September 30, 2014 and 2013, respectively.
	Acquired intangible assets
	The net book value of acquired intangible assets were as follows (in thousands):
		September 30,				December 31,
	Customer Agreements:	2014				2013
	Carrying value	$	410			$	410
	Accumulated amortization	(198		)		(75		)
	Intangible assets, net	$	212			$	335
	Weighted average remaining life (in years)	1.3				2
	On July 15, 2013, the Company capitalized approximately $5.9 million of intangible assets acquired in the Merger. $2.2 million of these intangible assets acquired were reclassified to discontinued operations and assets held for sale. The Company recognized $172,000 as amortization expense on the intangible assets for both three months and nine months ended September 30, 2013. Total amortization expense was $41,000 for the three months ended September 30, 2014 and $123,000 for the nine months ended September 30, 2014.
	As of September 30, 2014 expected amortization expense related to our purchased intangible assets is approximately $41,000 over the remainder of 2014 and $171,000 during 2015.
	Subsequent to the Merger with Tranzyme, during the third quarter 2013 review of the collaboration agreement with Bristol-Meyers Squibb Company ("BMS"), the Company determined that BMS would terminate its efforts on the development of one of two macrocyclic compounds under development pursuant to an on-going collaboration agreement. As a result, the Company recognized an impairment loss of 50% of the intangible asset value associated with the agreement The Company expensed $1.6 million as a result of this impairment during the three months ended September 30, 2013. No impairment charges were recorded in the three and nine months ended September 30, 2014.
	At December 31, 2013 the Company impaired 100% of the intangible asset associated with the agreement as a result of notification from BMS that all development efforts for all macrocyclic compounds would be terminated.
	Accrued Liabilities
	Accrued liabilities were as follows (in thousands):
		September 30,				December 31,
		2014				2013
	Accrued clinical trials	$	1,050			$	417
	Accrued compensation	449				1,093
	Accrued consulting	379				315
	Other accrued liabilities	36				77
	Total Accrued Liabilities	$	1,914			$	1,902

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stockholders' Equity	'
	Stockholders' Equity
	On July 10, 2014 the Company completed an underwritten public offering of its common stock in which 4,200,000 shares of common stock were sold by the Company. The aggregate gross proceeds from the offering were $25.2 million. After deducting underwriters' discounts and commissions and offering expense, the aggregate net proceeds received by the Company totaled approximately $23.4 million. The Company expects to use the net proceeds from the offering to continue its clinical development of OCR-002 and for working capital and other general corporate purposes.
	Stock Based Compensation
	The Company’s stock option activity and related information for the nine months ended September 30, 2014 was as follows (in thousands, except share and per share data):
											Weighted-avg.
		Shares					Weighted-avg.				Remaining	Aggregate
		Available		Stock Options			Exercise Price				Contractual	Intrinsic
		for Grant		Outstanding			Per Share				Life (in Years)	Value
	Balance at December 31, 2013	762,867		1,909,769			$	8.77			8.58	$	11,818
	Stock options granted	(894,000	)	894,000			$	7.44
	Stock options cancelled	364,551		(364,551	)		$	15.05
	Stock options exercised	—		(243,824	)		$	1.72
	Balance at September 30, 2014	233,418		2,195,394			$	7.97			9.16	$	547
	At September 30, 2014:
	Vested and expected to vest			2,114,917			$	7.98			9.14	$	547
	Exercisable			484,723			$	9.16			7.95	$	547
	The aggregate intrinsic value of options exercised under all option plans was $2.7 million and $44,000 for the nine months ended September 30, 2014 and 2013, respectively, determined as of the date of option exercise.
	The Company recognized stock based compensation expense as follows (in thousands):
		Three Months Ended							Nine Months Ended
		September 30,							September 30,
		2014			2013				2014			2013
	Research and development	$	528		$	2			$	1,359		$	6
	General and administrative	921			200				2,342			228
	Total	$	1,449		$	202			$	3,701		$	234
	As of September 30, 2014, there were unrecognized compensation costs of $13.4 million related to stock options and the Company expects to recognize those costs over a weighted average period of 3.10 years.
	Stock-based compensation cost for stock options is estimated at the grant date based on the fair-value using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options was estimated using the following weighted-average assumptions:
			Three Months Ended			Nine Months Ended
			September 30,			September 30,
			2014	2013		2014		2013
	Risk-free interest rates		1.85% - 2.00%	—		1.85% - 2.01%		—
	Expected life in years		6.08	—		6.08		—
	Expected dividend yield		—	—		—		—
	Expected volatility		97%	—		97% - 102%		—

Discontinued_Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2014
Discontinued Operations and Disposal Groups [Abstract]	'
Discontinued Operations	'
	Discontinued Operations
	On September 11, 2013, the Company announced a restructuring plan related to the operations of Tranzyme Pharma. On December 13, 2013, the Company entered into a Technology Transfer and License Agreement with Genentech, Inc. ("Genentech"), and F. Hoffman-La Roche, Ltd. ("Roche") to sell certain Canadian fixed assets and materials, the MATCH technology and rights to the Genentech and Roche customer agreements and related intellectual property through licensing of patents for $4.0 million. The Company concluded that the operations of Tranzyme Pharma and related asset groups sold to Genentech and Roche would be accounted for as discontinued operations as the operations and cash flows of the discontinued component or asset group would be eliminated from ongoing operations of the Company and there would not be significant involvement in the component or asset group after the disposal transaction.
	During the nine months ended September 30, 2014, the Company completed its obligations under the Technology Transfer and License Agreement with Genentech and Roche and recognized a gain on disposal of assets of $1.1 million within discontinued operations.
	The results of Tranzyme Pharma and related asset groups are disclosed as discontinued operations in the Consolidated Statements of Operations and Comprehensive Loss for the period presented (in thousands).
			Three Months Ended								Nine Months Ended
			September 30,								September 30,
			2014				2013				2014				2013
	Revenue		$	—			$	167			$	—			$	167
	Expenses:
	Research and development		—				(503		)		—				(503		)
	General and administrative		—				(168		)		—				(168		)
	Amortization of intangible assets		—				(93		)		—				(93		)
	Restructuring charges		—				(742		)		—				(742		)
	Gain on disposal of assets		—				—				1,149				—
	Settlement of certain restructuring charges		68				—				68				—
	Other income (loss) from discontinued operations		—				2				(6		)		2
	Recognition of accumulated translation adjustments upon deconsolidation of subsidiary		(10		)		—				(16		)		—
	Net income (loss) from discontinued operations		$	58			$	(1,337	)		$	1,195			$	(1,337	)
	The assets and liabilities of Tranzyme Pharma and related asset groups are presented as held for disposal in the Consolidated Balance Sheets as of September 30, 2014 and December 31, 2013. The carrying amount of assets and liabilities are as follows (in thousands):
		30-Sep-14				31-Dec-13
	Prepaid expenses and other current assets	$	—			$	178
	Property and equipment, net	—				356
	Intangible assets, net	—				2,053
	Goodwill	—				442
	Assets of discontinued operations	$	—			$	3,029
	Accounts payable	$	—			$	106
	Deposit on sale of assets	—				3,000
	Accrued liabilities	—				397
	Liabilities of discontinued operations	$	—			$	3,503
	Restructuring of Tranzyme Pharma
	Restructuring charges of $742,000 were recorded during the three months ended September 30, 2013. During the nine months ended September 30, 2014, the Company paid and settled all of the remaining liabilities related to the restructuring of Tranzyme Pharma.
	The following table summarizes the Company’s restructuring activities during the periods ended September 30, 2014 (in thousands):
		Post- Employment Benefits				Moving and Shipping Costs				Operating Activities				Total
	Restructuring charges during three months ended September 30, 2013	$	708			$	—			$	34			$	742
	Restructuring charges during three months ended December 31, 2013	(8		)		114				11				117
	Cash payments and other settlements	(308		)		(15		)		(34		)		(357		)
	Accrued restructuring at December 31, 2013	392				99				11				502
	Cash payments and other settlements	(392		)		(31		)		(11		)		(434		)
	Settlement of certain restructuring charges	—				(68		)		—				(68		)
	Accrued restructuring at September 30, 2014	$	—			$	—			$	—			$	—

License_Agreements_and_Acquire

License Agreements and Acquired Commercialization Rights	9 Months Ended
	Sep. 30, 2014
Intangible Assets, Net (Excluding Goodwill) [Abstract]	'
License Agreements and Acquired Commercialization Rights	'
	License Agreements and Acquired Commercialization Rights
	Lyric Pharmaceuticals, Inc.
	In September 2014, the Company entered into an Asset License and Purchase Agreement for the Sale and License of ulimorelin ("TZP-101"), the former lead compound of Tranzyme Inc., to Lyric Pharmaceuticals, Inc. (“Lyric”). Per the terms of the agreement, the Company received an up-front nonrefundable payment of $200,000 for the transfer of intellectual property and materials associated with TZP-101 and the licensing of associated patents with no further ongoing obligations to be performed by the Company. In addition, Lyric is solely responsible for the preclinical and clinical development of all products arising from the further development of TZP-101.
	If successful, the Company could receive future consideration as a percentage of the proceeds received by Lyric upon its sale or license to a third party, and under certain conditions, clinical and regulatory milestones totaling up to $25.0 million plus royalty payments from potential product sales generated by TZP-101.

Net_Loss_Per_Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Net Loss Per Share	'
	Net Loss Per Share
	Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include convertible preferred stock, warrants, convertible notes payable and outstanding stock options under the stock option plan have been excluded from the computation of diluted net loss per share as they would be anti-dilutive. For all periods presented, there is no difference in the number of shares used to compute basic and diluted shares outstanding due to the Company’s net loss position. All share and per share amounts for all periods presented in the following table have been adjusted retroactively to reflect the exchange for Tranzyme, shares as of the date of the Merger.
	The following table presents the computation of net loss per share (in thousands, except share and per share data):
		Three Months Ended							Nine Months Ended
		September 30,							September 30,
		2014				2013			2014			2013
	Numerator
	Net loss from continuing operations	$	(6,661	)		$	(6,065	)	$	(19,086	)	$	(8,883	)
	Net income (loss) from discontinued operations	58				(1,337		)	1,195			(1,337		)
	Net loss	$	(6,603	)		$	(7,402	)	$	(17,891	)	$	(10,220	)
	Denominator
	Weighted average common shares outstanding used to compute net loss per share, basic and diluted	19,330,888				9,669,320			16,778,047			3,683,156
	Net loss per share of common stock, basic and diluted
	Net loss per share from continuing operations	$	(0.34	)		$	(0.63	)	$	(1.14	)	$	(2.41	)
	Net income (loss) per share from discontinued operations	—				(0.14		)	0.07			(0.36		)
	Net loss per share	$	(0.34	)		$	(0.77	)	$	(1.07	)	$	(2.77	)
	The following weighted average outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014		2013
	Convertible preferred stock	—			736,570			—		3,472,405
	Convertible preferred stock warrants	—			2,003			—		14,902
	Common stock warrants	938,882			158,939			938,882		140,722
	Common stock options	1,985,217			633,163			1,827,527		573,789
	Total	2,924,099			1,530,675			2,766,409		4,201,818
	In addition to the potentially dilutive securities noted above, the Company had outstanding convertible notes payable and accrued interest that were converted into 186,217 shares of common stock upon completion of the Merger. The Company has excluded these convertible notes payable from the table above.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of its business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. The Company is currently not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on the Company's consolidated results of operations or financial position.
	Leases
	In August 2014, the Company amended the term of the lease for its North Carolina facility by extending term of the lease through January 2016. Rent expense was approximately $53,000 and $156,000 for the three and nine months ended September 30, 2014 and $79,000 and $153,000 for the three and nine months ended September 30, 2013, respectively.
	The following is a schedule of non-cancellable future minimum lease payments for operating leases as of September 30, 2014 (in thousands):
	Years ending December 31:
	2014 (Remaining Three Months)	$	56
	2015	191
	2016	14
	Total	$	261

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Accounting	'
	Basis of Presentation
	The Company has a limited operating history and the sales and income potential of the Company's business and addressable market are unproven. The Company anticipates that it will continue to incur net losses into the foreseeable future as it continues the development and commercialization of its lead drug candidate OCR-002 and expands its corporate infrastructure. Based on the Company's operating plan, the Company believes its current working capital is sufficient to fund its operations through at least the next twelve months.
	The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with United States of America generally accepted accounting principles ("U.S. GAAP") for interim financial statements and pursuant to the rules and regulations of the Securities and Exchange Commission. The financial statements and related notes do not include all information and footnotes required by U.S. GAAP for annual reports. This quarterly report should be read in conjunction with the consolidated financial statements included in the Company’s annual report on Form 10-K for the year ended December 31, 2013. Certain prior year amounts have been reclassified to conform with current year presentation.
Unaudited Interim Financial Information	'
	Unaudited Interim Financial Information
	The accompanying interim consolidated financial statements and related disclosures are unaudited, have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the results of operations for the periods presented. The year-end balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with the U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
Discontinued Operations	'
	Discontinued Operations
	On September 11, 2013, the Board of Directors approved a restructuring plan related to the operations of Tranzyme Pharma Inc. and its Sherbrooke, Quebec facility ("Tranzyme Pharma"), whereby the Company closed the operations of the facility effective as of November 11, 2013. On December 13, 2013, the Company entered into a Technology Transfer and License Agreement to sell the Company’s MATCH discovery platform and license the related intellectual property rights. The Company concluded that since Tranzyme Pharma's operations and the MATCH discovery platform comprised a component with distinct operations and cash flows that would be eliminated from ongoing operations, and the Company would not have significant involvement after the disposal, these components would be accounted for as discontinued operations. The results of operations of the components to be disposed of, related restructuring costs and gain on disposal of assets have been classified as net income (loss) from discontinued operations from their date of acquisition on July 15, 2013 through September 30, 2014. The assets and liabilities of Tranzyme Pharma have been classified as assets and liabilities, respectively, of discontinued operations. Discontinued operations are retroactively applied to all prior periods presented, and the financial statements presented for 2013 are reclassified to recognize the effects of discontinued operations. Unless noted otherwise, discussion in these notes to the financial statements pertain to our continuing operations.
Revenue Recognition	'
	Revenue Recognition
	The Company recognizes revenue from the delivery of collaborative research services, license agreements for the development and commercialization of products and from royalties. During 2013, collaboration research revenue is disclosed as discontinued operations in the Company’s Consolidated Statements of Operation and Comprehensive Loss for all periods presented. For each source of revenue, the Company applies revenue recognition criteria in the following manner:
	Multiple element arrangements such as collaboration agreements which may include an upfront license and ongoing services are analyzed to determine whether the deliverables within the agreement can be separated or whether they must be accounted for as a single unit of accounting. Deliverables under the agreement will be accounted for as separate units of accounting provided that (i) a delivered item has value to the customer on a stand-alone basis; and (ii) if the agreement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially in the control of the vendor. The allocation of consideration amongst the deliverables under the agreement is derived using a "best estimate of selling price" if vendor specific objective evidence and third-party evidence of fair value is not available. If the delivered element does not have stand-alone value, the arrangement is then accounted for as a single unit of accounting, and the Company will recognize the consideration received under the arrangement as revenue on a straight-line basis over the estimated period of performance.
	License fees from license agreements are recognized when the amounts are earned and determinable during the applicable period. The Company recognizes up-front nonrefundable license fees when due under contractual agreements and when the Company does not have a continuing obligation to provide services related to the agreement. Revenue associated with nonrefundable up-front license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting is deferred and recognized as revenue on a straight-line basis over the expected term of our continued involvement in the research and development process.
	The Company recognizes royalty payments as revenue when earned. At the end of each accounting period, estimates of royalty amounts due are made based on estimated sales information from the Company's customers.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In April 2014, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update, or ASU, No. 2014-08, Presentation of Financial Statements (Topic 205) and Property, Plant and Equipment (topic 360); Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. ASU 2014-08 provides additional requirements to classify a disposal of a component of an entity or a group of components of an entity in discontinued operations only if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2014, with an option for early adoption. The Company intends to adopt this guidance at the beginning of our first quarter of fiscal year 2015, and does not expect the adoption of this standard will have a material impact on the Company’s financial statements.
	On May 28, 2014, the FASB issued Accounting Standards Update, or ASU, No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard will become effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.
	In June 2014, the FASB issued Accounting Standards Update, or ASU, No. 2014-10, Development Stage Entities (Topic 915). ASU 2014-10 removes the distinction between development stage entities and other reporting entities in U.S. GAAP and eliminates the requirement to label financial statements as those of a development stage entity and eliminates the requirement to present inception to date information in the statements of income, cash flows and shareholder equity. The guidance is applied retroactively and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2014, with an option for early adoption. The Company early adopted this guidance in the second quarter of 2014, and as a result, has removed the label “A Development Stage Company” from its financial statements and accompanying notes and eliminated the inception to date information from the Consolidated Statements of Operations and Comprehensive Loss and Consolidated Statements of Cash Flows. Other than presentation, the adoption of this standard did not have a material impact on the Company’s financial statements.
	In August 2014, the FASB issued Accounting Standards Update, or ASU, No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. In doing so, companies will have reduced diversity in the timing and content of footnote disclosures than under today’s guidance. ASU 2014-15 is effective for the Company in the first quarter of 2016 with early adoption permitted. The Company does not believe the impact of adopting this standard will be material on the Company's financial statements.
Net Loss Per Share	'
	Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. Potentially dilutive securities which include convertible preferred stock, warrants, convertible notes payable and outstanding stock options under the stock option plan have been excluded from the computation of diluted net loss per share as they would be anti-dilutive. For all periods presented, there is no difference in the number of shares used to compute basic and diluted shares outstanding due to the Company’s net loss position. All share and per share amounts for all periods presented in the following table have been adjusted retroactively to reflect the exchange for Tranzyme, shares as of the date of the Merger.

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Assets and liabilities measured at fair value on a recurring basis	'
	Assets measured at fair value on a recurring basis as of September 30, 2014 are as follows (in thousands):
		Balance as of		Quoted Prices		Significant		Significant
		September 30,		in Active		Other		Unobservable
		2014		Markets for		Observable		Inputs
				Identical Assets		Inputs		(Level 3)
				(Level 1)		(Level 2)
	Assets:
	Money market funds	$	7,445	$	7,445	$	—	$	—
	Commercial paper	5,250		—		5,250		—
	Corporate debt securities	42,053		—		42,053		—
	Total assets	$	54,748	$	7,445	$	47,303	$	—
	Assets measured at fair value on a recurring basis as of December 31, 2013 are as follows (in thousands):
		Balance as of		Quoted Prices		Significant		Significant
		December 31,		in Active		Other		Unobservable
		2013		Markets for		Observable		Inputs
				Identical Assets		Inputs		(Level 3)
				(Level 1)		(Level 2)
	Assets:
	Money market funds	$	5,774	$	5,774	$	—	$	—
	Commercial paper	15,246		—		15,246		—
	Corporate debt securities	20,884		—		20,884		—
	Total assets	$	41,904	$	5,774	$	36,130	$	—

Balance_Sheet_Components_Table

Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2014
Balance Sheet Components [Abstract]	'
Summary of available for sale investments	'
	The following table summarizes the Company's available for sale investments as of September 30, 2014 (in thousands).
			Maturity (in Years)		Amortized Cost				Unrealized Gains		Unrealized Losses			Estimated Fair Value
	Short-term investments:
	Commercial paper		1 or less		5,246				4		—			5,250
	Corporate debt securities		1 or less		41,671				—		(10		)	41,661
	Total				46,917				4		(10		)	46,911
	Long-term investments:
	Corporate debt securities		More than 1		392				—		—			392
	Total				392				—		—			392
	Total investments				$	47,309			$	4	$	(10	)	$	47,303
	The following table summarizes the Company's available for sale investments as of December 31, 2013 (in thousands).
			Maturity (in Years)		Amortized Cost				Unrealized Gains		Unrealized Losses			Estimated Fair Value
	Short-term investments:
	Commercial paper		1 or less		$	15,232			$	14	$	—		$	15,246
	Corporate debt securities		1 or less		14,930				—		(9		)	14,921
	Total				30,162				14		(9		)	30,167
	Long-term investments:
	Corporate debt securities		More than 1		1,515				—		(2		)	1,513
	Total				1,515				—		(2		)	1,513
	Total investments				$	31,677			$	14	$	(11	)	$	31,680
Property and equipment components	'
	Property and equipment, net were as follows (in thousands):
		Useful Life		September 30,				December 31,
		(in years)		2014				2013
	Computer equipment and software	3 years		$	53			$	40
	Office furniture and equipment	5 years		68				43
				121				83
	Accumulated depreciation			(52		)		(24		)
	Property and equipment, net			$	69			$	59
Net book value of acquired intangible assets	'
	The net book value of acquired intangible assets were as follows (in thousands):
		September 30,				December 31,
	Customer Agreements:	2014				2013
	Carrying value	$	410			$	410
	Accumulated amortization	(198		)		(75		)
	Intangible assets, net	$	212			$	335
	Weighted average remaining life (in years)	1.3				2
Schedule of accrued liabilities	'
	Accrued liabilities were as follows (in thousands):
		September 30,				December 31,
		2014				2013
	Accrued clinical trials	$	1,050			$	417
	Accrued compensation	449				1,093
	Accrued consulting	379				315
	Other accrued liabilities	36				77
	Total Accrued Liabilities	$	1,914			$	1,902

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Summary of stock option activity	'
	The Company’s stock option activity and related information for the nine months ended September 30, 2014 was as follows (in thousands, except share and per share data):
											Weighted-avg.
		Shares					Weighted-avg.				Remaining	Aggregate
		Available		Stock Options			Exercise Price				Contractual	Intrinsic
		for Grant		Outstanding			Per Share				Life (in Years)	Value
	Balance at December 31, 2013	762,867		1,909,769			$	8.77			8.58	$	11,818
	Stock options granted	(894,000	)	894,000			$	7.44
	Stock options cancelled	364,551		(364,551	)		$	15.05
	Stock options exercised	—		(243,824	)		$	1.72
	Balance at September 30, 2014	233,418		2,195,394			$	7.97			9.16	$	547
	At September 30, 2014:
	Vested and expected to vest			2,114,917			$	7.98			9.14	$	547
	Exercisable			484,723			$	9.16			7.95	$	547
Stock-based compensation expense	'
	The Company recognized stock based compensation expense as follows (in thousands):
		Three Months Ended							Nine Months Ended
		September 30,							September 30,
		2014			2013				2014			2013
	Research and development	$	528		$	2			$	1,359		$	6
	General and administrative	921			200				2,342			228
	Total	$	1,449		$	202			$	3,701		$	234
Stock option valuation assumptions	'
	The fair value of employee stock options was estimated using the following weighted-average assumptions:
			Three Months Ended			Nine Months Ended
			September 30,			September 30,
			2014	2013		2014		2013
	Risk-free interest rates		1.85% - 2.00%	—		1.85% - 2.01%		—
	Expected life in years		6.08	—		6.08		—
	Expected dividend yield		—	—		—		—
	Expected volatility		97%	—		97% - 102%		—

Discontinued_Operations_Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2014
Discontinued Operations and Disposal Groups [Abstract]	'
Discontinued operations included the Income Statement and Balance Sheets	'
	The results of Tranzyme Pharma and related asset groups are disclosed as discontinued operations in the Consolidated Statements of Operations and Comprehensive Loss for the period presented (in thousands).
			Three Months Ended								Nine Months Ended
			September 30,								September 30,
			2014				2013				2014				2013
	Revenue		$	—			$	167			$	—			$	167
	Expenses:
	Research and development		—				(503		)		—				(503		)
	General and administrative		—				(168		)		—				(168		)
	Amortization of intangible assets		—				(93		)		—				(93		)
	Restructuring charges		—				(742		)		—				(742		)
	Gain on disposal of assets		—				—				1,149				—
	Settlement of certain restructuring charges		68				—				68				—
	Other income (loss) from discontinued operations		—				2				(6		)		2
	Recognition of accumulated translation adjustments upon deconsolidation of subsidiary		(10		)		—				(16		)		—
	Net income (loss) from discontinued operations		$	58			$	(1,337	)		$	1,195			$	(1,337	)
	The assets and liabilities of Tranzyme Pharma and related asset groups are presented as held for disposal in the Consolidated Balance Sheets as of September 30, 2014 and December 31, 2013. The carrying amount of assets and liabilities are as follows (in thousands):
		30-Sep-14				31-Dec-13
	Prepaid expenses and other current assets	$	—			$	178
	Property and equipment, net	—				356
	Intangible assets, net	—				2,053
	Goodwill	—				442
	Assets of discontinued operations	$	—			$	3,029
	Accounts payable	$	—			$	106
	Deposit on sale of assets	—				3,000
	Accrued liabilities	—				397
	Liabilities of discontinued operations	$	—			$	3,503
Schedule of estimated expenses to be incurred and expensed	'
	The following table summarizes the Company’s restructuring activities during the periods ended September 30, 2014 (in thousands):
		Post- Employment Benefits				Moving and Shipping Costs				Operating Activities				Total
	Restructuring charges during three months ended September 30, 2013	$	708			$	—			$	34			$	742
	Restructuring charges during three months ended December 31, 2013	(8		)		114				11				117
	Cash payments and other settlements	(308		)		(15		)		(34		)		(357		)
	Accrued restructuring at December 31, 2013	392				99				11				502
	Cash payments and other settlements	(392		)		(31		)		(11		)		(434		)
	Settlement of certain restructuring charges	—				(68		)		—				(68		)
	Accrued restructuring at September 30, 2014	$	—			$	—			$	—			$	—

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Computation of net loss per share	'
	The following table presents the computation of net loss per share (in thousands, except share and per share data):
		Three Months Ended							Nine Months Ended
		September 30,							September 30,
		2014				2013			2014			2013
	Numerator
	Net loss from continuing operations	$	(6,661	)		$	(6,065	)	$	(19,086	)	$	(8,883	)
	Net income (loss) from discontinued operations	58				(1,337		)	1,195			(1,337		)
	Net loss	$	(6,603	)		$	(7,402	)	$	(17,891	)	$	(10,220	)
	Denominator
	Weighted average common shares outstanding used to compute net loss per share, basic and diluted	19,330,888				9,669,320			16,778,047			3,683,156
	Net loss per share of common stock, basic and diluted
	Net loss per share from continuing operations	$	(0.34	)		$	(0.63	)	$	(1.14	)	$	(2.41	)
	Net income (loss) per share from discontinued operations	—				(0.14		)	0.07			(0.36		)
	Net loss per share	$	(0.34	)		$	(0.77	)	$	(1.07	)	$	(2.77	)
Potentially dilutive securities not included in the calculation of dilutive net loss per share	'
	The following weighted average outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014		2013
	Convertible preferred stock	—			736,570			—		3,472,405
	Convertible preferred stock warrants	—			2,003			—		14,902
	Common stock warrants	938,882			158,939			938,882		140,722
	Common stock options	1,985,217			633,163			1,827,527		573,789
	Total	2,924,099			1,530,675			2,766,409		4,201,818
	In addition to the potentially dilutive securities noted above, the Company had outstanding convertible notes payable and accrued interest that were converted into 186,217 shares of common stock upon completion of the Merger. The Company has excluded these convertible notes payable from the table above.

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of non-cancellable future minimum lease payments for operating leases	'
	The following is a schedule of non-cancellable future minimum lease payments for operating leases as of September 30, 2014 (in thousands):
	Years ending December 31:
	2014 (Remaining Three Months)	$	56
	2015	191
	2016	14
	Total	$	261

The_Company_Details

The Company (Details) (USD $)	0 Months Ended	9 Months Ended
	Jul. 10, 2014	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Class of Stock [Line Items]	'	'	'	'
Proceeds from issuance of common stock, net of issuance costs	$23,400,000	$23,439,000	$19,973,000	'
Accumulated deficit	'	-99,377,000	'	-81,486,000
Cash, cash equivalents and investments	'	55,600,000	'	'
Common Stock | IPO	'	'	'	'
Class of Stock [Line Items]	'	'	'	'
Stock issued (in shares)	4,200,000	'	'	'
Gross proceeds from stock offering	$25,200,000	'	'	'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (Recurring [Member], USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	$54,748	$41,904
Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	7,445	5,774
Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	47,303	36,130
Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	0	0
Money Market Funds [Member] | Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	7,445	5,774
Money Market Funds [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	7,445	5,774
Money Market Funds [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	0	0
Money Market Funds [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	0	0
Commercial Paper [Member] | Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	5,250	15,246
Commercial Paper [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	0	0
Commercial Paper [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	5,250	15,246
Commercial Paper [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	0	0
Corporate Debt Securities [Member] | Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	42,053	20,884
Corporate Debt Securities [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	0	0
Corporate Debt Securities [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	42,053	20,884
Corporate Debt Securities [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Total assets	$0	$0

Balance_Sheet_Components_Avail

Balance Sheet Components (Available For Sale Investments) (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	$47,309	$31,677
Unrealized Gains	4	14
Unrealized Losses	-10	-11
Estimated Fair Value	47,303	31,680
Short-term investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	46,917	30,162
Unrealized Gains	4	14
Unrealized Losses	-10	-9
Estimated Fair Value	46,911	30,167
Short-term investments [Member] | Commercial Paper [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	5,246	15,232
Unrealized Gains	4	14
Unrealized Losses	0	0
Estimated Fair Value	5,250	15,246
Short-term investments [Member] | Corporate Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	41,671	14,930
Unrealized Gains	0	0
Unrealized Losses	-10	-9
Estimated Fair Value	41,661	14,921
Long-term investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	392	1,515
Unrealized Gains	0	0
Unrealized Losses	0	-2
Estimated Fair Value	392	1,513
Long-term investments [Member] | Corporate Debt Securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	392	1,515
Unrealized Gains	0	0
Unrealized Losses	0	-2
Estimated Fair Value	$392	$1,513

Balance_Sheet_Components_Prope

Balance Sheet Components (Property and Equipment) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	$121	'	$121	'	$83
Less accumulated depreciation	-52	'	-52	'	-24
Property and equipment, net	69	'	69	'	59
Depreciation expense	8	11	28	15	'
Computer equipment and software [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	53	'	53	'	40
Useful life	'	'	'3 years	'	'
Office furniture and equipment [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property and equipment, gross	$68	'	$68	'	$43
Useful life	'	'	'5 years	'	'

Balance_Sheet_Components_Acqui

Balance Sheet Components (Acquired Intangible Assets) (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Jul. 15, 2013
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'
Carrying value	$410,000	'	$410,000	'	$410,000	'
Accumulated amortization	-198,000	'	-198,000	'	-75,000	'
Intangible assets, net	212,000	'	212,000	'	335,000	'
Weighted average remaining life (in years)	'	'	'1 year 3 months 18 days	'	'2 years	'
Intangible assets held for sale	'	'	'	'	'	2,200,000
Amortization of intangibles	41,000	172,000	123,000	172,000	'	'
Estimated future amortization expense in 2014	41,000	'	41,000	'	'	'
Estimated future amortization expense in 2015	171,000	'	171,000	'	'	'
Percentage of intangible assets impaired	'	50.00%	'	50.00%	100.00%	'
Impairment of intangibles	0	1,576,000	0	1,576,000	'	'
Tranzyme Inc. [Member]	'	'	'	'	'	'
Acquired Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'
Intangible assets, net	'	'	'	'	'	$5,900,000

Balance_Sheet_Components_Accru

Balance Sheet Components (Accrued Liabilities) (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Balance Sheet Components [Abstract]	'	'
Accrued clinical trials	$1,050	$417
Accrued compensation	449	1,093
Accrued consulting	379	315
Other accrued liabilities	36	77
Accrued liabilities	$1,914	$1,902

Stockholders_Equity_Stock_Opti

Stockholders' Equity (Stock Option Activity) (Details) (Stock Options [Member], USD $)	9 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Stock Options [Member]	'	'
Shares Available for Grant	'	'
Shares available for grant	762,867	'
Stock options granted	-894,000	'
Stock options cancelled	364,551	'
Shares available for grant	233,418	762,867
Stock Options Outstanding	'	'
Beginning balance, options	1,909,769	'
Stock options granted	894,000	'
Stock options cancelled	-364,551	'
Stock options exercised	-243,824	'
Ending balance, options	2,195,394	1,909,769
Stock options vested and expected to vest	2,114,917	'
Stock options exercisable	484,723	'
Weighted-average Exercise Price Per Share	'	'
Weighted-average exercise price, options outstanding, beginning balance	$8.77	'
Grants in period	$7.44	'
Cancelled in period	$15.05	'
Exercises in period	$1.72	'
Weighted-average exercise price, options outstanding, ending balance	$7.97	$8.77
Weighted-average exercise price, options exercisable	$7.98	'
Weighted-average exercise price, options vested and expected to vest	$9.16	'
Weighted-average remaining contractual life, options outstanding	'9 years 1 month 28 days	'8 years 6 months 29 days
Weighted-average remaining contractual life, options vested and expected to vest	'9 years 1 month 21 days	'
Weighted-average remaining contractual life, options exercisable	'7 years 11 months 12 days	'
Aggregate Intrinsic value, options outstanding	$547	$11,818
Aggregate Intrinsic value, options vested and expected to vest	547	'
Aggregate Intrinsic value, options exercisable	$547	'

Stockholders_Equity_Stockbased

Stockholders' Equity (Stock-based compensation expense) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	$1,449	$202	$3,701	$234
Research and Development [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	528	2	1,359	6
General and Administrative [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Stock-based compensation expense	$921	$200	$2,342	$228

Stockholders_Equity_Valuation_

Stockholders' Equity (Valuation Assumptions) (Details) (Stock Options [Member])	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Stock Options [Member]	'	'	'	'
Fair Value Assumptions and Methodology [Abstract]	'	'	'	'
Risk free interest rate	'	0.00%	'	0.00%
Risk free interest rate, minimum	1.85%	'	1.85%	'
Risk free interest rate, maximum	2.00%	'	2.01%	'
Expected life in years	'6 years 29 days	'	'6 years 29 days	'
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Expected volatility	97.00%	0.00%	'	0.00%
Expected volatility, minimum	'	'	97.00%	'
Expected volatility, maximum	'	'	102.00%	'

Stockholders_Equity_Additional

Stockholders' Equity (Additional Information) (Details) (USD $)	0 Months Ended	9 Months Ended
	Jul. 10, 2014	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Proceeds from issuance of common stock, net of issuance costs	$23,400,000	$23,439,000	$19,973,000
Aggregate intrinsic value of options exercised	'	2,700,000	44,000
Stock Options	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Compensation costs not yet recognized	'	13,400,000	'
Period for recognizing costs	'	'3 years 1 month 6 days	'
IPO | Common Stock	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Stock issued (in shares)	4,200,000	'	'
Gross proceeds from stock offering	$25,200,000	'	'

Discontinued_Operations_Detail

Discontinued Operations (Details) (USD $)	3 Months Ended	9 Months Ended		3 Months Ended			9 Months Ended
	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 13, 2013
				Tranzyme Pharma Inc. [Member]	Tranzyme Pharma Inc. [Member]	Tranzyme Pharma Inc. [Member]	Tranzyme Pharma Inc. [Member]	Tranzyme Pharma Inc. [Member]	Tranzyme Pharma Inc. [Member]
									Customer Agreements And Intellectual Property [Member]
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'	'
Sale price for discontinued operations	'	'	'	'	'	'	'	'	$4,000,000
Gain on disposal of assets	0	1,149,000	'	0	'	0	1,149,000	0	'
Restructuring charges	'	'	$742,000	$0	$117,000	$742,000	$0	$742,000	'

Discontinued_Operations_Discon

Discontinued Operations (Discontinued Operations in the Company's Consolidated Statements of Operations and Comprehensive Loss) (Details) (USD $)	3 Months Ended			9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'	'
Restructuring charges	'	'	'	'	($742)
Gain on disposal of assets	0	'	'	1,149	'
Net income (loss) from discontinued operations	58	'	-1,337	1,195	-1,337
Tranzyme Pharma Inc. [Member]	'	'	'	'	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'	'
Revenue	0	'	167	0	167
Research and development	0	'	-503	0	-503
General and administrative	0	'	-168	0	-168
Amortization of intangible assets	0	'	-93	0	-93
Restructuring charges	0	-117	-742	0	-742
Gain on disposal of assets	0	'	0	1,149	0
Settlement of certain restructuring charges	68	'	0	68	0
Other income (loss) from discontinued operations	0	'	2	-6	2
Recognition of accumulated translation adjustments upon deconsolidation of subsidiary	-10	'	0	-16	0
Net income (loss) from discontinued operations	$58	'	($1,337)	$1,195	($1,337)

Discontinued_Operations_Discon1

Discontinued Operations (Discontinued Operations in the Company's Consolidated Statement of Financial Position) (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'
Assets of discontinued operations	$0	$3,029
Tranzyme Pharma Inc. [Member]	'	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'
Prepaid expenses and other current assets	0	178
Property and equipment	0	356
Intangible assets, net	0	2,053
Goodwill	0	442
Assets of discontinued operations	0	3,029
Accounts payable	0	106
Deposit on sale of assets	0	3,000
Accrued liabilities	0	397
Liabilities of discontinued operations	$0	$3,503

Discontinued_Operations_Restru

Discontinued Operations (Restructuring Activities) (Details) (USD $)	3 Months Ended			9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'
Restructuring charges	'	'	'	'	$742
Tranzyme Pharma Inc. [Member]	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'
Restructuring charges	0	117	742	0	742
Restructuring Reserve [Roll Forward]	'	'	'	'	'
Accrued Restructuring at Start of Period	'	'	'	502	'
Cash payments and other settlements	'	-357	'	-434	'
Settlement of certain restructuring charges	-68	'	0	-68	0
Accrued Restructuring at End of Period	0	502	'	0	'
Tranzyme Pharma Inc. [Member] | Post-Employment Benefits [Member]	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'
Restructuring charges	'	-8	708	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'	'
Accrued Restructuring at Start of Period	'	'	'	392	'
Cash payments and other settlements	'	-308	'	-392	'
Settlement of certain restructuring charges	'	'	'	0	'
Accrued Restructuring at End of Period	0	392	'	0	'
Tranzyme Pharma Inc. [Member] | Moving and Shipping Costs [Member]	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'
Restructuring charges	'	114	0	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'	'
Accrued Restructuring at Start of Period	'	'	'	99	'
Cash payments and other settlements	'	-15	'	-31	'
Settlement of certain restructuring charges	'	'	'	-68	'
Accrued Restructuring at End of Period	0	99	'	0	'
Tranzyme Pharma Inc. [Member] | Operating Activities [Member]	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'
Restructuring charges	'	11	34	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'	'
Accrued Restructuring at Start of Period	'	'	'	11	'
Cash payments and other settlements	'	-34	'	-11	'
Settlement of certain restructuring charges	'	'	'	0	'
Accrued Restructuring at End of Period	$0	$11	'	$0	'

License_Agreements_and_Acquire1

License Agreements and Acquired Commercialization Rights (Details) (USD $)	3 Months Ended		9 Months Ended		1 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014
					Intellectual Property And Licensing Agreements [Member]
Indefinite-lived Intangible Assets [Line Items]	'	'	'	'	'
Up-front nonrefundable payment received	$200,000	$0	$200,000	$0	$200,000
Future contingent consideration	'	'	'	'	$25,000,000

Net_Loss_Per_Share_Schedule_of

Net Loss Per Share (Schedule of Basic and Diluted Loss Per Share) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Numerator	'	'	'	'
Net loss from continuing operations	($6,661)	($6,065)	($19,086)	($8,883)
Net income (loss) from discontinued operations	58	-1,337	1,195	-1,337
Net loss	($6,603)	($7,402)	($17,891)	($10,220)
Denominator	'	'	'	'
Weighted average common shares outstanding used to compute net loss per share, basic and diluted	19,330,888	9,669,320	16,778,047	3,683,156
Net loss per share of common stock, basic and diluted	'	'	'	'
Net loss per share from continuing operations	($0.34)	($0.63)	($1.14)	($2.41)
Net income per share from discontinued operations	$0	($0.14)	$0.07	($0.36)
Net loss per share, basic and diluted	($0.34)	($0.77)	($1.07)	($2.77)

Net_Loss_Per_Share_Schedule_of1

Net Loss Per Share (Schedule of Antidilutive Securities Excluded From Earnings Per Share) (Details)	0 Months Ended	3 Months Ended		9 Months Ended
	Jul. 15, 2013	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount	'	2,924,099	1,530,675	2,766,409	4,201,818
Conversion of notes payable and interest accrued excluded from diluted earnings per share	186,217	'	'	'	'
Convertible Preferred Stock [Member]	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount	'	0	736,570	0	3,472,405
Convertible Preferred Stock [Member] | Warrants [Member]	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount	'	0	2,003	0	14,902
Common Stock [Member] | Warrants [Member]	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount	'	938,882	158,939	938,882	140,722
Common Stock [Member] | Stock Options [Member]	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount	'	1,985,217	633,163	1,827,527	573,789

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'	'	'	'
Rent expense	$53	$79	$156	$153
Future Minimum Payments Due by Fiscal Year Maturity [Abstract]	'	'	'	'
2014 (Remaining Three Months)	56	'	56	'
2015	191	'	191	'
2016	14	'	14	'
Total	$261	'	$261	'